Alexion Pharmaceuticals

2010 Archives

Monday, December 6, 2010

Long-Term Efficacy, Safety and Survival Outcomes of PNH Patients Treated with Soliris® (eculizumab) Reported at ASH Annual Meeting
Monday, December 6, 2010

Hemolysis Is Associated with Increased Mortality and Thrombosis in Patients with PNH
Sunday, December 5, 2010

Alexion Reports Results from First Clinical Trial of Novel Anti-Cancer Antibody Samalizumab at ASH Annual Meeting
Wednesday, November 24, 2010

Alexion to Present at the Piper Jaffray 22nd Annual Health Care Conference
Saturday, November 20, 2010

Phase 2 Study of Eculizumab (Soliris®) in Patients with aHUS Resistant to Plasma Therapy Met Primary and Secondary Endpoints with High Statistical and Clinical Significance
Monday, November 8, 2010

Researchers to Present New Long-Term Data on Soliris® (eculizumab) in Patients with PNH at the ASH Annual Meeting
Thursday, November 4, 2010

Alexion to Present at the Credit Suisse 2010 Healthcare Conference
Wednesday, October 27, 2010

Alexion to Present at the Oppenheimer 21st Annual Healthcare Conference
Thursday, October 21, 2010

Alexion Reports Third Quarter 2010 Results
Wednesday, October 20, 2010

Alexion Announces Interim Results from Phase 2 Trials of Eculizumab (Soliris(R)) in Patients with atypical Hemolytic Uremic Syndrome (aHUS)
Thursday, October 7, 2010

Alexion Pharmaceuticals to Report Third Quarter Results on Thursday, October 21, 2010
Monday, September 27, 2010

Alexion Pharmaceuticals Earns the Connecticut Green Building Council Green Advocate Award and Two LEED Gold Certifications for Environmental Sustainability
Tuesday, September 14, 2010

Alexion to Present at the UBS Global Life Sciences Conference
Tuesday, September 7, 2010

Alexion to Present at Investor Conferences
Monday, August 23, 2010

Alexion Receives FDA Approval of Rhode Island Manufacturing Facility for Soliris(R) Supply
Thursday, July 22, 2010

Alexion Reports Second Quarter 2010 Results
Monday, July 12, 2010

Alexion Pharmaceuticals to Report Second Quarter Results on Thursday, July 22, 2010
Tuesday, June 15, 2010

Early Clinical Experience and Basic Science Support Further Investigation of Soliris(R) (eculizumab) for the Treatment of Patients with Thrombotic Microangiopathy
Monday, June 14, 2010

Substantial Disease Burden of PNH Demonstrated in Data from International and Asian Patient Registries Presented at European Hematology Association
Wednesday, June 2, 2010

Alexion to Present at Investor Conferences
Wednesday, June 2, 2010

Alexion Accelerates Plans to Launch Soliris(R) (Eculizumab) in Japan
Tuesday, June 1, 2010

Alexion Announces the Appointment of Ann M. Veneman to Its Board of Directors
Wednesday, May 19, 2010

Alexion to Present at the Citi 2010 Global Health Care Conference
Friday, April 30, 2010

Research to be Presented at the American Transplant Congress Examines the Role of Terminal Complement Inhibition in the Treatment of Kidney Transplantation Patients
Thursday, April 22, 2010

Alexion Reports First Quarter 2010 Results
Tuesday, April 20, 2010

Alexion Completes Enrollment in All Four Clinical Trials of Soliris(R) (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Friday, April 16, 2010

Alexion's Soliris(R) (Eculizumab) Receives Marketing Approval in Japan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Thursday, April 8, 2010

Alexion Pharmaceuticals to Report First Quarter Results on Thursday, April 22, 2010
Tuesday, March 2, 2010

Alexion to Present at the Cowen and Company 30th Annual Health Care Conference
Friday, February 26, 2010

Alexion Joins NORD, EURORDIS and Other Patient Advocacy Groups in Supporting the Goals of Rare Disease Day 2010
Wednesday, February 24, 2010

Alexion Appoints Andreas Rummelt to its Board of Directors
Thursday, February 11, 2010

Alexion Reports Fourth Quarter and Full Year 2009 Results
Thursday, January 28, 2010

Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2009 Results on February 11, 2010
Wednesday, January 6, 2010

Alexion to Present at the 28th Annual JP Morgan Healthcare Conference